Oren Gilad - Oct 23, 2024 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role
President/CEO, Director
Signature
/s/ John P. Hamill, as Attorney-in-Fact
Stock symbol
APRE
Transactions as of
Oct 23, 2024
Transactions value $
$1,958
Form type
4
Date filed
10/24/2024, 08:30 AM
Previous filing
Oct 16, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APRE Common Stock Purchase $1.96K +500 +0.15% $3.92 333K Oct 23, 2024 Direct F1
holding APRE Common Stock 1.2K Oct 23, 2024 By Daughter F2
holding APRE Common Stock 600 Oct 23, 2024 By Son F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.91 to $3.92, inclusive. The reporting person undertakes to provide to the issuer or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
F2 The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.